Zobrazeno 1 - 10
of 91
pro vyhledávání: '"ad5-ncov"'
Autor:
Hui Zheng, Cuidan Li, Xiuyu Zheng, Hu-Dachuan Jiang, Yuqing Li, Aihua Yao, Xiaolong Li, Feiyu Wang, Wenqing Liu, Xiang Cao, Runjie Qi, Li Chen, Lairun Jin, Fengcai Zhu, Jingxin Li, Fei Chen
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundHeterologous booster vaccines are more effective than homologous booster vaccines in combating the coronavirus disease 2019 (COVID-19) outbreak. However, our understanding of homologous and heterologous booster vaccines for COVID-19 remains
Externí odkaz:
https://doaj.org/article/2d1ed8ebc30c495f89ca5f1d05f2b58e
Autor:
Zhe Zhang, Xiang-Yang Chi, Guan-Ying Zhang, Zhang Zhang, Song-He Lu, Meng-Jing Li, Liang-Jun Li, Jin-Long Zhang, Fang-Ze Shao, Yue Zhang, Li-Hua Hou, Wei Chen
Publikováno v:
Emerging Microbes and Infections, Vol 13, Iss 1 (2024)
We administered a questionnaire to participants who received different vaccination regimens to evaluate the effectiveness of Ad5-vectored COVID-19 vaccines. The results showed that administration of intramuscular Ad5-nCoV provided 21.32% more protect
Externí odkaz:
https://doaj.org/article/2629f1225294404cbee5f64e2670eb3a
Autor:
Yan-Fei Wu, Ming-Wei Wei, Rui-Jie Wang, Xi-Ling Guo, Hong-Xing Pan, Ya-Chun Gao, Xiao-Long Li, Xue Wang, Xiao-Min Ma, Peng Wan, Li Zhou, Ya-Wen Zhu, Jing-Xin Li, Feng-Cai Zhu
Publikováno v:
Expert Review of Vaccines, Vol 22, Iss 1, Pp 662-670 (2023)
Background The certification of immunogenicity consistency at different production scales is indispensable for the quality control of vaccines. Research design and methods A randomized, double-blind immunobridging trial in healthy adults aged 18–59
Externí odkaz:
https://doaj.org/article/1e2755170b9d486cb62e59abc4ffbf40
Publikováno v:
Expert Review of Vaccines, Vol 22, Iss 1, Pp 704-713 (2023)
Introduction The global spread of COVID-19 has prompted the development of vaccines. A recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) developed by Chinese scientists has been authorized for use as a prime and booster dose in China
Externí odkaz:
https://doaj.org/article/57cdbd44217b4a9aa8f6b3954a5dcab6
Autor:
Xu Han, Mingwei Wei, Xiuyu Zheng, Peng Wan, Jie Tang, Lu Zhang, Shupeng Zhang, Hanchi Zhou, Jiayu Lu, Li Zhou, Yawen Zhu, Jingxin Li, Fengcai Zhu
Publikováno v:
Vaccines, Vol 12, Iss 6, p 683 (2024)
Background: Though children infected by SARS-CoV-2 generally experience milder symptoms compared to adults, severe cases can occur. Additionally, children can transmit the virus to others. Therefore, the availability of safe and effective COVID-19 va
Externí odkaz:
https://doaj.org/article/fb78c95340dc4f94ad4d19b7a39911e4
Autor:
Fuzhen Wang, Baoying Huang, Yao Deng, Shaobai Zhang, Xiaoqiang Liu, Lei Wang, Qianqian Liu, Li Zhao, Lin Tang, Wenling Wang, Xiaoqi Wang, Fei Ye, Weijun Hu, Haitao Yang, Siquan Wang, Jiao Ren, Xiaoyu Liu, Cangning Wang, Xuhua Guan, Ruize Wang, Yan Zheng, Xianfeng Zhang, Hui Zheng, Dan Wu, Zhijie An, Wenbo Xu, Lawrence E. Rodewald, George F. Gao, Zundong Yin, Wenjie Tan
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-10 (2023)
Abstract Background Several COVID-19 vaccines are in widespread use in China. Few data exist on comparative immunogenicity of different COVID-19 vaccines given as booster doses. We aimed to assess neutralizing antibody levels raised by injectable and
Externí odkaz:
https://doaj.org/article/f7d5516c1cf343608adda37949afd285
Autor:
Yawen Zhu, Rong Tang, Xiaolong Li, Xiaoqin Chen, Xue Wang, Ying Wang, Ruijie Wang, Fengcai Zhu, Jingxin Li
Publikováno v:
Vaccines, Vol 12, Iss 3, p 292 (2024)
This randomized, double-blind, placebo-controlled phase 1/2 trial aimed at evaluating the safety and immunogenicity of Ad5-nCoV via aerosolized or intramuscular or intramuscular–aerosolized routes in SARS-CoV-2-negative adults aged over 18 years. I
Externí odkaz:
https://doaj.org/article/d08196925575424e823e5107cb70df1c
Autor:
Zhe Zhang, Shipo Wu, Yawei Liu, Kailiang Li, Pengfei Fan, Xiaohong Song, Yudong Wang, Zhenghao Zhao, Xianwei Zhang, Jin Shang, Jinlong Zhang, Jinghan Xu, Yao Li, Yaohui Li, Jipeng Zhang, Kefan Fu, Busen Wang, Meng Hao, Guanying Zhang, Pengwei Long, Ziyu Qiu, Tao Zhu, Shuling Liu, Yue Zhang, Fangze Shao, Peng Lv, Yilong Yang, Xiaofan Zhao, Yufa Sun, Lihua Hou, Wei Chen
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionThe SARS-CoV-2 Omicron variant has become the dominant SARS-CoV-2 variant and exhibits immune escape to current COVID-19 vaccines, the further boosting strategies are required.MethodsWe have conducted a non-randomized, open-label and para
Externí odkaz:
https://doaj.org/article/f9fc742ab4244a7c8d34a26dc8db413e
Autor:
Nani Xu, Yu Xu, Rongrong Dai, Lin Zheng, Pan Qin, Peng Wan, Yejing Yang, Jianmin Jiang, Hangjie Zhang, Xiaowei Hu, Huakun Lv
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionChina experienced a record surge of coronavirus disease 2019 cases in December 2022, during the pandemic.MethodsWe conducted a randomized, parallel-controlled prospective cohort study to evaluate efficacy and antibody duration after a fou
Externí odkaz:
https://doaj.org/article/9f235e9271e148a89db977d933b3236d
Autor:
Jia-Lu Feng, Wen-Juan Wang, Peng-Fei Jin, Hui Zheng, Lai-Run Jin, Xin Xia, Xiao-Yin Zhang, Zhuo-Pei Li, Jing-Xin Li, Feng-Cai Zhu
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)
This post-hoc analysis compared the receptor-binding domain (RBD)-specific and pseudovirus neutralizing antibodies against the wild-type SARS-CoV-2 strain elicited by one or two doses (56-d interval) of Ad5-nCoV vaccine regimen (NCT04341389 and NCT04
Externí odkaz:
https://doaj.org/article/b6ec16beba044ac4a123b33b7bad66b4